CO2021000223A2 - Composiciones farmaceuticas en forma liofilizada - Google Patents

Composiciones farmaceuticas en forma liofilizada

Info

Publication number
CO2021000223A2
CO2021000223A2 CONC2021/0000223A CO2021000223A CO2021000223A2 CO 2021000223 A2 CO2021000223 A2 CO 2021000223A2 CO 2021000223 A CO2021000223 A CO 2021000223A CO 2021000223 A2 CO2021000223 A2 CO 2021000223A2
Authority
CO
Colombia
Prior art keywords
group
pharmaceutical compositions
disaccharide
lyophilized form
substance selected
Prior art date
Application number
CONC2021/0000223A
Other languages
English (en)
Inventor
Oliver Denk
Original Assignee
Breath Therapeutics Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Breath Therapeutics Gmbh filed Critical Breath Therapeutics Gmbh
Publication of CO2021000223A2 publication Critical patent/CO2021000223A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7016—Disaccharides, e.g. lactose, lactulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A61K38/13—Cyclosporins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dispersion Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)

Abstract

La invención se relaciona con una composición farmacéutica liofilizada para reconstitución en un portador líquido acuoso que comprende: a) estructuras formadoras de liposoma que comprenden i. una cantidad terapéuticamente efectiva de ciclosporina A (CsA); ii. una sustancia formadora de membrana seleccionada del grupo de fosfolípidos; y iii. una sustancia mejoradora de solubilidad seleccionada de grupo de tensoactivos no iónicos; y b) por lo menos un disacárido seleccionado del grupo que consiste de sacarosa, lactosa y trehalosa, en donde el por lo menos un disacárido está presente en una cantidad de por lo menos 40% en peso con relación al peso total de la composición liofilizada
CONC2021/0000223A 2018-06-27 2021-01-14 Composiciones farmaceuticas en forma liofilizada CO2021000223A2 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP18180177 2018-06-27
PCT/EP2019/066875 WO2020002353A1 (en) 2018-06-27 2019-06-25 Pharmaceutical compositions in lyophilized form

Publications (1)

Publication Number Publication Date
CO2021000223A2 true CO2021000223A2 (es) 2021-01-18

Family

ID=62814888

Family Applications (1)

Application Number Title Priority Date Filing Date
CONC2021/0000223A CO2021000223A2 (es) 2018-06-27 2021-01-14 Composiciones farmaceuticas en forma liofilizada

Country Status (12)

Country Link
US (2) US20210244664A1 (es)
EP (1) EP3813788A1 (es)
JP (1) JP7401471B2 (es)
CN (1) CN113038930A (es)
AU (1) AU2019295027B2 (es)
BR (1) BR112020026629A2 (es)
CA (1) CA3104445A1 (es)
CO (1) CO2021000223A2 (es)
EA (1) EA202092893A1 (es)
IL (1) IL279760A (es)
MX (1) MX2020013831A (es)
WO (1) WO2020002353A1 (es)

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4857319A (en) * 1985-01-11 1989-08-15 The Regents Of The University Of California Method for preserving liposomes
EP0208764A4 (en) 1985-01-11 1987-10-08 Univ California PRESERVATION PROCEDURE FOR LIPOSOME.
US4963362A (en) 1987-08-07 1990-10-16 Regents Of The University Of Minnesota Freeze-dried liposome mixture containing cyclosporin
DE69211691T2 (de) 1991-04-19 1997-01-16 Nexstar Pharmaceuticals Inc., Boulder, Col. Pharmazeutische formulierung und pharmazeutisches verfahren
WO1996040064A1 (en) 1995-06-07 1996-12-19 Nexstar Pharmaceuticals, Inc. Liposomal cyclosporin formulations as agents for immunosuppression and multiple drug resistant indications
TW497974B (en) 1996-07-03 2002-08-11 Res Dev Foundation High dose liposomal aerosol formulations
US5958378A (en) 1996-07-03 1999-09-28 Research Development Foundation High dose liposomal aerosol formulations containing cyclosporin A or budesonide
IT1289938B1 (it) 1997-02-20 1998-10-19 Angelini Ricerche Spa Preparazione farmaceutica comprendente liposomi liofilizzati in cui e' incapsulato un principio attivo altamente insolubile in acqua e
AU2003237863A1 (en) 2002-05-20 2003-12-12 Research Development Foundation Aerosol drug inhibition of lung metastases
EP1687635A2 (en) * 2003-11-26 2006-08-09 Applera Corporation Ligand-containing micelles and uses thereof
CN1960707B (zh) * 2004-06-03 2012-11-14 博莱科瑞士股份有限公司 用于治疗和/或诊断用途的脂质集合体
DE102006051512A1 (de) 2005-12-06 2007-06-14 Pari GmbH Spezialisten für effektive Inhalation Pharmazeutische Medikamentenzusammensetzungen mit Cyclosporin
JP2009519250A (ja) 2005-12-08 2009-05-14 ワイス リポソーム組成物
EP1797895A1 (en) * 2005-12-16 2007-06-20 Pevion Biotech Ltd. An adjuvant system comprising virosomes and liposomes
US20110070294A1 (en) * 2009-09-23 2011-03-24 Javeri Indu Methods for the Administration of Drugs Using Liposomes
US20140127288A1 (en) * 2011-05-17 2014-05-08 Mitsubishi Gas Chemical Company, Inc. Liposome containing pyrroloquinoline quinone and sugar
EP3069711A1 (en) 2015-03-16 2016-09-21 PARI Pharma GmbH Cyclosporine formulations for use in the prevention or treatment of pulmonary chronic graft rejection

Also Published As

Publication number Publication date
US20210244664A1 (en) 2021-08-12
US20230301914A1 (en) 2023-09-28
EA202092893A1 (ru) 2021-04-19
MX2020013831A (es) 2021-03-25
IL279760A (en) 2021-03-01
AU2019295027B2 (en) 2024-09-19
AU2019295027A1 (en) 2020-12-24
JP7401471B2 (ja) 2023-12-19
WO2020002353A1 (en) 2020-01-02
EP3813788A1 (en) 2021-05-05
JP2021528450A (ja) 2021-10-21
CA3104445A1 (en) 2020-01-02
CN113038930A (zh) 2021-06-25
BR112020026629A2 (pt) 2021-03-23

Similar Documents

Publication Publication Date Title
PE20200513A1 (es) Formulaciones estables de anticuerpos contra el receptor de muerte programada 1 (pd-1) y metodos para su uso
PE20141159A1 (es) Metodos para tratar o prevenir trastornos relacionados con el colesterol
ECSP23041058A (es) Formulación subcutánea de anticuerpo anti-her2
ES2981519T3 (es) Formulaciones de virus adeno-asociados
CL2018003178A1 (es) Composición farmacéutica
AR050127A1 (es) Composicion detergente solida altamente soluble en agua que forma un licor de lavado cristalino cuando se disuelve en agua.
PE20190469A1 (es) Formulaciones, kits y metodos de anticuerpos inhibidores de masp-2 de baja viscosidad altamente concentrados
SG11201807765PA (en) Antibody-containing preparation
AR095396A1 (es) Formulaciones de anticuerpo
CO6280464A2 (es) Formulacion de anticuerpo cd20
AR089787A1 (es) Formulaciones estabilizadas que contienen anticuerpos anti-ang2
AR115283A1 (es) Composiciones sólidas que comprenden un agonista del glp-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílicoe
AR100268A1 (es) Formulación líquida que comprende compuesto neutralizante de gm-csf
ECSP066817A (es) Productos de película que tienen propiedades de disgregación controlada
AR093584A1 (es) Inmunoglobulinas heterodimericas
CL2019001049A1 (es) Vacuna contra parvovirus porcino.
RU2012125254A (ru) Составы антитела
CL2019002513A1 (es) Composiciones de limpieza cosmética.
UY35755A (es) Coformulaciones de bifentrina con agentes de protección de cultivos encapsulados para uso con fertilizantes líquidos
AR095496A1 (es) Formulaciones de anticuerpos anti-receptor de prolactina
HRP20220011T1 (hr) Nova stabilna formulacija za fxia protutijela
CO2019003876A2 (es) Formulación farmacéutica parenteral que contiene ácido carglúmico
CO2021000223A2 (es) Composiciones farmaceuticas en forma liofilizada
MX2020003718A (es) Composiciones y metodos para el tratamiento de fibrosis.
BR112014030623A2 (pt) composição, combinação e respectivos usos